Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript

Bausch Health's CFO reintroduced the company as a global, diversified pharmaceutical and medical devices group operating in 70+ markets and organized in five segments (including Bausch + Lomb). The current corporate configuration dates from 2015 following large, debt‑financed acquisitions such as Salix, Bausch + Lomb and Solta Medical, and management noted a historical focus on lenders rather than equity investors; outside Bausch + Lomb the business includes U.S. pharma (Salix), a diversified portfolio, and international platforms concentrated in Eastern Europe, Latin America and Canada.

Analysis

Market structure: Bausch (BHC) is a classic debt-overhang story — winners are well-capitalized ophthalmic/device peers and secured creditors if a debt-for-equity or asset-sale path emerges; losers are BHC equity and subordinated bondholders absent a clear deleveraging plan. Pricing power in key Bausch + Lomb franchises (contact lenses, surgical optics) should support cash flow, but leverage constrains capex and M&A, compressing long-term market share versus nimbler peers. Expect demand for eye-care products to remain inelastic (low single-digit organic growth), so shocks will be credit-driven not product-driven.

Risk assessment: Tail risks include a covenant breach or Chapter 11 filing within 6–18 months if refinancing windows close — low-probability but high-impact (equity near-total loss, unsecured recovery <30c). Immediate (0–30 days) risk is volatility and spread widening; short-term (3–9 months) hinges on refinancing/deleveraging announcements; long-term (12–36 months) depends on asset-sale proceeds and EBITDA trajectory. Hidden dependencies: LatAm FX exposure can swing EBITDA by ±10–20% and lenders may accelerate maturities; catalytic events are Q4 results, covenant tests, and any formal exchange offer within 90 days.

Trade implications: Establish a tactical short BHC equity position sized 2–3% NAV and buy 6–12 month ATM puts as cheap downside insurance if no credible deleveraging by next quarter; alternatively buy 1–3 year CDS protection or purchase senior secured paper only if yields exceed 9% (price <75) targeting 12–24 month hold. Pair trade: long BLCO (or standalone Bausch + Lomb equities/bonds) 1–2% vs short BHC 2–3% to play capital structure dispersion over 6–12 months. Rotate 3–5% of healthcare exposure away from leveraged pharma into well-capitalized device names (e.g., Alcon/JNJ) over next 3 months.

Contrarian angles: Consensus underprices the option value of stable Bausch + Lomb cash flows — if management commits to selling non-core assets and reduces net debt/EBITDA below 4.0x within 12 months, unsecured bonds could rally 300–500bps and equity could retrace 30–50% from troughs. Reaction may be overdone in equity today but underdone in bonds if lenders quickly compromise (recovery >40%); historical parallel: post-acquisition leverage resets (Valeant/Mylan) show outcomes diverge on management credibility and creditor incentives. Monitor net debt/EBITDA, 2028–2030 bond yields, and any formal exchange offer within 90 days as decision triggers.

Key Decisions for Investors

• Initiate a short BHC equity position sized 2–3% of NAV within 30 days; hedge with 6–12 month ATM puts (buy puts equal to 50–75% of notional) to protect against a covenant breach or filing over the next 6–12 months.
• Buy 1–3 year CDS protection on BHC or purchase senior secured BHC bonds only if yield-to-worst >9% (implying price <75); target hold 12–24 months and aim for 20–35% IRR conditional on successful deleveraging or refinancing.
• Establish a pair trade: long BLCO equity/bonds 1–2% vs short BHC equity 2–3%, horizon 6–12 months — play capital structure arbitrage assuming BLCO (Bausch + Lomb) retains higher cash-flow multiple and lower leverage.
• Rotate 3–5% of healthcare exposure away from leveraged specialty pharma into well-capitalized device names (tactically ALcon/Johnson & Johnson or equivalents) over the next 4–12 weeks to reduce credit-risk beta.
• Set hard monitoring triggers: exit or trim equity shorts if net debt/EBITDA falls below 4.0x or BHC unsecured bond yields tighten by >300bps within 90 days; add to credit longs if recovery prospects improve (formal asset-sale proceeds announced).